Noninvasive imaging to detect PD-L1 in gastrointestinal tumors
PD-L1 Targeting Molecular Imaging of Solid Tumors
This study is testing a new imaging method to see if it can help find a specific marker in gastrointestinal tumors that might show which patients could benefit from certain cancer treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04629326 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a noninvasive imaging technique using WL12 PET/CT to detect PD-L1 expression in tumor lesions of patients with gastrointestinal tumors. By identifying PD-L1 expression, the study seeks to determine which patients may benefit from anti-PD-1/L1 therapies. The approach involves measuring the expression of PD-L1 in solid tumors, which could help tailor treatment strategies for better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with measurable gastrointestinal tumors and a life expectancy of at least 12 weeks.
Not a fit: Patients with significant hepatic or renal dysfunction, or those who cannot tolerate the imaging procedure, may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to more personalized treatment options for patients with gastrointestinal tumors.
How similar studies have performed: While this approach is innovative, similar studies targeting PD-L1 expression have shown promise in other cancer types, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged \>18 years old; ECOG 0 or 1; * 2\. Patients with Gastrointestinal tumors; * 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1); * 4\. life expectancy \>=12 weeks. Exclusion Criteria: * 1\. Significant hepatic or renal dysfunction; * 2\. Is pregnant or ready to pregnant; * 3\. Cannot keep their states for half an hour; * 4\. Refusal to join the clinical study; * 5\. Suffering from claustrophobia or other mental diseases; * 6\. Any other situation that researchers think it is not suitable to participate in the experiment.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Hua Zhu
- Email: zhuhuabch@pku.edu.cn
- Phone: 010-88196495
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.